Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-50520
Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.
![[img]](http://www.zora.uzh.ch/style/images/fileicons/application_pdf.png) | Accepted Version PDF - Registered users only 440Kb |
Abstract
VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.
| Item Type: | Journal Article, refereed, original work |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology |
| DDC: | 610 Medicine & health |
| Language: | English |
| Date: | 2011 |
| Deposited On: | 10 Nov 2011 15:13 |
| Last Modified: | 29 Nov 2012 11:43 |
| Publisher: | American Academy of Neurology |
| ISSN: | 0028-3878 |
| Publisher DOI: | 10.1212/WNL.0b013e31822f02e1 |
| PubMed ID: | 21880994 |
| WoS Citation Count: | 21 |
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page
